...an observer at companies including Turning Point Therapeutics Inc. (NASDAQ:TPTX), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and Peloton Therapeutics Inc....

...that it acquired through its takeout of Peloton Therapeutics Inc....

...an expanded management team that now includes Genentech veteran Lisa Bowers and the addition of former Peloton Therapeutics Inc....

...Svennilson and Nextech’s Thilo Schroeder joined Circle’s board, and John Josey, who was CEO of Peloton Therapeutics Inc....

...made a pair of multibillion-dollar bolt-on acquisitions, taking out ArQule Inc. for $2.7 billion and Peloton Therapeutics Inc....

...Inc. (NASDAQ:BBIO) hired Eli Wallace as CSO in residence for oncology. Wallace was CSO of Peloton Therapeutics Inc....

...product in preclinical through Phase II testing for other solid cancers. Two HIF2A inhibitors from Peloton Therapeutics Inc....

...improve on standard-of-care treatments. For example, another of its exits came from the sale of Peloton Therapeutics Inc....

...Inc. (NASDAQ:AMGN) Nuevolution AB (SSE:NUE) 05/21/19 $167.1 NA NA $167.1 Merck & Co. Inc. (NYSE:MRK) Peloton Therapeutics Inc....

...slated to start a Phase I/II trial in 1H20 Rather than complete its proposed listing, Peloton Therapeutics Inc....